State of the Science Summit on Hematologic Malignancies | Conference

Brentuximab Vedotin Solidified in Hodgkin Lymphoma, But Toxicity Concerns Remain

January 6th 2020

Seo-Hyun Kim, MD, discusses frontline treatment considerations in stage III and IV classical Hodgkin lymphoma and exciting combinations on the horizon.

Ongoing Research Poised to Add Options for Myelofibrosis Treatment

January 3rd 2020

Jamile M. Shammo, MD, FASCP, FACP, discusses the current treatment paradigm of myelofibrosis, criteria for ruxolitinib resistance and intolerance, and promising agents on the horizon.

Novel Agents Strengthen Treatment Armamentarium in Non-Hodgkin Lymphoma

January 3rd 2020

Parameswaran Venugopal, MD, discusses current and emerging treatment strategies in non-Hodgkin lymphoma.

AML Research Efforts in Full Swing After Decades of Stagnation

December 28th 2019

Melissa L. Larson, MD, discusses available treatments for patients with acute myeloid leukemia, as well as others that are in the pipeline.

Exploration With Blinatumomab and CAR T-Cell Therapy Continues in ALL

December 22nd 2019

Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.

Novel Agents and Combos Continue to Transform Myeloma Paradigm

December 17th 2019

Agne Paner, MD, discusses the treatment paradigm in multiple myeloma and promising agents on the horizon.

Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCL

July 30th 2019

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Dr. Hou on Polatuzumab Vedotin in DLBCL

July 25th 2019

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the use of polatuzumab vedotin (Polivy) in diffuse large B-cell lymphoma (DLBCL).

Dr. Hou on the Latest Updates With CAR T-Cell Therapy in DLBCL

July 19th 2019

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Dr. Redner on the Potency of Gilteritinib in AML

July 19th 2019

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the potency of gilteritinib (Xospata) in acute myeloid leukemia (AML).